Published in N Engl J Med on April 10, 2014
Mechanisms and Management of Exercise Intolerance in Older Heart Failure Patients | NCT03111017
International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail (2015) 2.03
Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction. Circulation (2015) 2.02
Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation (2015) 1.96
Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circulation (2015) 1.64
Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res (2014) 1.56
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J (2015) 1.46
Improved Cardiovascular Disease Outcomes in Older Adults. F1000Res (2016) 1.43
One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. Circ Heart Fail (2016) 1.39
Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol (2014) 1.27
Lessons from the TOPCAT trial. N Engl J Med (2014) 1.26
Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail (2015) 1.25
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J (2014) 1.25
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation (2016) 1.14
Clinical Characteristics and Outcome of Acute Heart Failure in Korea: Results from the Korean Acute Heart Failure Registry (KorAHF). Korean Circ J (2017) 1.01
Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol (2015) 0.95
Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem. J Geriatr Cardiol (2015) 0.95
Heart failure with preserved ejection fraction in the elderly: scope of the problem. J Mol Cell Cardiol (2015) 0.93
A 70-year-old woman with heart failure with preserved ejection fraction. CMAJ (2014) 0.91
Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction. Hypertension (2015) 0.90
Impact of Sleep-Disordered Breathing on Long-Term Outcomes in Patients With Acute Coronary Syndrome Who Have Undergone Primary Percutaneous Coronary Intervention. J Am Heart Assoc (2016) 0.88
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 0.88
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 0.88
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 0.88
Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice. Am J Physiol Heart Circ Physiol (2015) 0.88
Understanding heart failure with preserved ejection fraction: where are we today? Neth Heart J (2016) 0.87
Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. J Am Heart Assoc (2016) 0.87
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 0.87
Reducing RBM20 activity improves diastolic dysfunction and cardiac atrophy. J Mol Med (Berl) (2016) 0.87
Role of mineralocorticoid receptor antagonists in cardiovascular disease. Circ Res (2015) 0.85
Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review. Heart Fail Rev (2015) 0.84
Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. Am Heart J (2014) 0.84
Impaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction. J Am Heart Assoc (2014) 0.84
Enabling a Learning Health System through a Unified Enterprise Data Warehouse: The Experience of the Northwestern University Clinical and Translational Sciences (NUCATS) Institute. Clin Transl Sci (2015) 0.83
International collaboration: promises and challenges. Rambam Maimonides Med J (2015) 0.83
Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue. Circ Heart Fail (2016) 0.81
Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators. Clin Chim Acta (2014) 0.81
MicroRNA and Heart Failure. Int J Mol Sci (2016) 0.81
Causes and predictors of hospital readmissions in patients older than 65 years hospitalized for heart failure with preserved left ventricular ejection fraction in western Romania. Clin Interv Aging (2015) 0.81
Evaluation of Short-Term Changes in Serum Creatinine Level as a Meaningful End Point in Randomized Clinical Trials. J Am Soc Nephrol (2015) 0.81
Non-sirtuin histone deacetylases in the control of cardiac aging. J Mol Cell Cardiol (2015) 0.81
Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circ Heart Fail (2016) 0.81
Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure? Heart Fail Rev (2015) 0.80
Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. Vasc Health Risk Manag (2015) 0.80
Targeting heart failure with preserved ejection fraction: current status and future prospects. Vasc Health Risk Manag (2016) 0.80
Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials. BMC Med (2015) 0.80
Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review. J Am Heart Assoc (2015) 0.80
Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc (2016) 0.79
Imaging for assessment of sudden death risk: current role and future prospects. Europace (2016) 0.78
Diastolic dysfunction. Circ J (2015) 0.78
Recent advances in treatment of heart failure. F1000Res (2015) 0.78
Is there a new dawn for selective mineralocorticoid receptor antagonism? Curr Opin Nephrol Hypertens (2014) 0.78
Breakthrough in heart failure with preserved ejection fraction: are we there yet? Korean J Intern Med (2015) 0.78
Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. Expert Opin Pharmacother (2017) 0.78
Site selection for heart failure clinical trials in the USA. Heart Fail Rev (2015) 0.78
Response to Endurance Exercise Training in Older Adults with Heart Failure with Preserved or Reduced Ejection Fraction. J Am Geriatr Soc (2017) 0.78
Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. Curr Heart Fail Rep (2017) 0.78
Detection and Management of Geographic Disparities in the TOPCAT Trial: Lessons Learned and Derivative Recommendations. JACC Basic Transl Sci (2016) 0.77
Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear Cardiology. Am J Med (2015) 0.77
Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circ Heart Fail (2015) 0.77
The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial. Clin J Am Soc Nephrol (2015) 0.77
Renin-Angiotensin Activation and Oxidative Stress in Early Heart Failure with Preserved Ejection Fraction. Biomed Res Int (2015) 0.77
Potential Expanded Indications for Neprilysin Inhibitors. Curr Heart Fail Rep (2017) 0.76
Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview. J Cardiovasc Transl Res (2017) 0.76
Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect. Clin Res Cardiol (2015) 0.76
Impact of Race, Ethnicity, and Multimodality Biomarkers on the Incidence of New-Onset Heart Failure With Preserved Ejection Fraction (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol (2016) 0.76
Heart failure: gaps in knowledge and failures in treatment. PLoS Med (2014) 0.76
Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction. Curr Opin Cardiol (2015) 0.76
From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure. Heart Lung Circ (2016) 0.76
Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction. J Cardiovasc Transl Res (2017) 0.76
Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy? Heart Fail Rev (2016) 0.75
Impact of hyperkalaemia definition on incidence assessment: implications for epidemiological research based on a large cohort study in newly diagnosed heart failure patients in primary care. BMC Fam Pract (2016) 0.75
The Impact Exerted on Clinical Outcomes of Patients With Chronic Heart Failure by Aldosterone Receptor Antagonists: A Meta-Analysis of Randomized Controlled Trials. J Clin Med Res (2016) 0.75
Treating Heart Failure with Preserved Ejection Fraction: A Challenge for Clinicians. Hosp Pharm (2015) 0.75
Heart Failure Stages Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study. Circulation (2016) 0.75
Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex-DHF pilot study. ESC Heart Fail (2016) 0.75
Role of mineralocorticoid receptor activation in cardiac diastolic dysfunction. Biochim Biophys Acta (2016) 0.75
Biomarkers of acute kidney injury and associations with short- and long-term outcomes. F1000Res (2016) 0.75
Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes? J Okla State Med Assoc (2016) 0.75
National quality assessment evaluating spironolactone use during hospitalization for acute myocardial infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE)-Retrospective AMI Study, 2001, 2006, and 2011. J Am Heart Assoc (2015) 0.75
Neprilysin inhibition: a brief review of past pharmacological strategies for heart failure treatment and future directions. Cardiol J (2016) 0.75
Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations. Circ Heart Fail (2017) 0.75
Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis. BMC Cardiovasc Disord (2016) 0.75
Patient-Centred Care of Older Adults With Cardiovascular Disease and Multiple Chronic Conditions. Can J Cardiol (2016) 0.75
Recent Patient Characteristics and Medications at Admission and Discharge in Hospitalized Patients With Heart Failure. J Clin Med Res (2015) 0.75
Effect of low-dose diuretics on the level of serum cystatin C and prognosis in patients with asymptomatic chronic heart failure. Exp Ther Med (2015) 0.75
What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold? Open Heart (2015) 0.75
Review of the top 5 cardiology studies of 2013-14. Can Pharm J (Ott) (2015) 0.75
Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure. Methodist Debakey Cardiovasc J (2016) 0.75
Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction. Am J Cardiol (2017) 0.75
Heart failure with preserved ejection fraction and skeletal muscle physiology. Heart Fail Rev (2017) 0.75
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 0.75
Advances in the management of heart failure: the role of ivabradine. Vasc Health Risk Manag (2016) 0.75
Towards 'Eternal Youth' of cardiac and skeletal muscle. Glob Cardiol Sci Pract (2015) 0.75
Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review. Open Heart (2016) 0.75
Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Ann Intern Med (2014) 0.75
Facts and numbers on epidemiology and pharmacological treatment of heart failure with preserved ejection fraction. ESC Heart Fail (2015) 0.75
Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm. Br J Pharmacol (2016) 0.75
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med (2005) 27.36
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr (2010) 13.12
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med (2012) 6.42
Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 6.36
Erectile dysfunction and subsequent cardiovascular disease. JAMA (2005) 6.22
Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med (2006) 6.15
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA (2013) 5.31
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med (2010) 5.23
Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA (2013) 5.19
Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med (2014) 4.88
Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med (2014) 4.86
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med (2012) 4.72
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA (2003) 4.44
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Imputation of missing data when measuring physical activity by accelerometry. Med Sci Sports Exerc (2005) 4.14
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.14
Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation (2007) 4.11
Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging. J Am Coll Cardiol (2006) 4.10
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care (2010) 4.10
Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA (2011) 4.09
Aggressive fluid and sodium restriction in acute decompensated heart failure: a randomized clinical trial. JAMA Intern Med (2013) 4.05
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA (2005) 3.89
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch Intern Med (2009) 3.73
Aortic diameter, wall stiffness, and wave reflection in systolic hypertension. Hypertension (2007) 3.68
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J (2008) 3.64
Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation (2010) 3.63
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation (2006) 3.40
From the Cover: Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci U S A (2008) 3.39
Controversies in ventricular remodelling. Lancet (2006) 3.39
The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med (2015) 3.36
Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. Am Heart J (2007) 3.34